Potential anti-ATL therapeutic vaccine using short-term cultured autologous peripheral blood mononuclear cells: preclinical evidence in vitro and in vivo

Kannagi M\textsuperscript{1,2}, Hasegawa A\textsuperscript{2,3}, Utsunomiya A\textsuperscript{4}, Akari H\textsuperscript{5}

\textsuperscript{1}Microbiology, Kansai Medical University, \textsuperscript{2}Immunotherapeutics, Tokyo Medical and Dental University, \textsuperscript{3}Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, \textsuperscript{4}Hematology, Imamura General Hospital, \textsuperscript{5}Center for Human Evolution Modeling Research, Primate Research Institute, Kyoto University

Background:
A recent clinical study of Tax peptide-pulsed dendritic cell vaccine suggests that activation of Tax-specific CTL can be a new therapeutic concept for adult T-cell leukemia (ATL). Here, we aimed to develop another immunotherapy for ATL to activate Tax-specific CTL without HLA limitation by using short-term cultured patients’ own PBMCs as a vaccine that contain HTLV-1 expressing cells.

Methods:
In in vitro system, mitomycin C (MMC)-treated HTLV-1-infected T-cells from ATL patients were co-cultured with antigen presenting cells (APCs), and the APC function to evoke CTL response (e.g. antigen cross-presentation, expression of co-stimulatory molecules and cytokine production) was examined. In in vivo system, Japanese macaques naturally infected with simian T-lymphotropic virus type 1 (STLV-1), closely related to HTLV-1, were vaccinated with short-term cultured own PBMCs following MMC-treatment.

Results:
The APCs co-cultured with short-term cultured PBMCs or HTLV-1-infected T-cell lines derived from ATL patients could cross-present Tax antigen on the MHC-I to activate CD8+ Tax-specific CTL. This effect was not a result of de novo infection in the APC, as it was not affected by a reverse transcriptase inhibitor. The co-cultured APCs also expressed IL-12 and CD86, while the levels of expression varied. Pre-treatment of the HTLV-1-infected cells with HDAC inhibitors improved these APC functions. In naturally STLV-1-infected Japanese monkeys, STLV-1 antigens were undetectable in fresh PBMCs but inducible following culture as observed in humans. We inoculated short-term cultured autologous PBMCs into STLV-1-
infected monkeys that had exhibited low CTL response, and found that STLV-1-specific CTLs were markedly activated.

Conclusion:
Short-term cultured autologous PBMCs from ATL patients expressing HTLV-1 antigens potentially act as a therapeutic vaccine to activate CTL responses.

Disclosure of Interest Statement:
No pharmaceutical grants were received in the development of this study.

Acknowledgement of Funding
This study was funded in part by Japan Agency for Medical Research and Development.